Somatic growth in hypothyroid pups and adults was only partially corrected by GH therapy. We conclude that GH treatment of hypothyroid animals normalized serum IGF-I levels in the hypothyroid rat pup, but did not correct their prolonged IGFBP-2 expression.
In the mature animal, serum IGF-I levels were partially corrected and IGFBP-3 levels were normalized by GH, but no change could be induced in the reduced serum IGFBP-4 levels. All the above changes were normalized by thyroid hormone replacement.
Thus, the effects of thyroid hormone on serum IGF levels and IGFBP-3 expression seem to be mediated indirectly via GH. The effects on IGFBP-2 ontogeny, and IGFBP-4 expression in the mature animal, however, are either direct thyroid hormone effects, or mediated by some other route, independent of GH, IGFs, or IGF receptors. (Endocrinology 132: 781-788, 1993) B OTH thyroid hormone and GH are essential for normal growth. The concept of a GH-insulin-like growth factor (IGF) axis as the major mechanism mediating the effects of GH has been well defined (1, 2), although its function has not yet been elucidated in every detail. The mechanism of thyroid hormone action on somatic growth is less completely understood.
As thyroid hormone is required for normal GH expression both in vitro (3-9) and in uivo (lo), its growth effects have been explained by the ability of thyroid hormone to promote GH secretion (3-10). Thyroid hormone has also been shown to affect the binding of GH to rat liver membranes, indicating regulation also at the level of the GH receptor (11). Another indirect mechanism suggested for Tq action is regulation of IGF-I receptor expression in peripheral tissues (12). The rat in viva model has been extensively used in attempts to understand the role of thyroid hormone on growth (12) (13) (14) (15) (16) (17) (18) from the first postnatal day. Another group (H + GH; n = 6) received human recombinant GH (Genentech, Inc., South San Francisco, CA) 7.5 pg/g body weight SC in a volume of 10 PI/g body weight (24) from the fifth postnatal day. This dose has been shown to normalize the reduced IGF-I levels in hypophysectomized neonatal rat pups (24) or adult hypophysectomized-thyroid replaced animals (Nan&Salonen, K., unpublished observations). Hypothyroid untreated pups (H; n = 4) and control animals (C; n = 4) were injected daily with equivalent volumes of the vehicle. All the pups were killed at the age of 18 days. Adult male rats were made hypothyroid by daily SC injections of methimazole (40 fig/g body weight) for 14 days. After that period, one group (H + T; n = 4) received Tq replacement (25 rig/g body weight), and another group (H + GH; n = 4, received GH replacement (7.5 wg/ g body weight) SC; untreated hypothyroid (H; n = 4) and control animals (C; n = 3) were injected with vehicle.
Growth parameters
At 3-to 4-day intervals, body weights were measured on a digital scale (S300D Fisher Scientific) and tail lengths of the pups (from the anus to the tip of the tail) were measured as an index of skeletal growth.
Biological samples
At the end of the experiment, animals were killed by decapitation. Blood was collected from the cervical stumps, allowed to clot at +4 C for 30 min and centrifuged at 10,000 rpm for 15 min to separate serum. The serum samples were stored at -20 C until analyzed.
Livers (H + T; v), and hypothyroid, GH-replaced animals (H + GH; V). Newborn hypothyroid pups were treated with T, from the first day of life, and with GH from the fifth day of life until killed at the age of 18 days. The adult animals were on goitrogen for 14 days, and then treated also with either T, or GH for 7 days. Control animals were injected with saline. Each group included four individual animals, except GH-treated pups (n = 6) and adult controls (n = 3).
for human IGFBP-3 was a 1082 bp EcoRI-PvuII restriction fragment from the 5'-end of the human IGFBP-3 cDNA, isolated from a human liver cDNA library, and contained the entire coding region (30 Mean and SD for each group are given, and statistical significance of the differences compared to respective control group are indicated (oneway ANOVA followed by Bonferroni t test. As the anti-rat GH antibody used in the RIA does not cross-react with the hGH used in the study, the serum rGH levels of the GH-treated hypothyroid pups were expectedly low.
a P c 0.001. *P < 0.005. ' GH determinations were done only from two samples.
A. significantly different from control group; P < 0.05) in body weight and very little subsequent weight gain after the induction of hypothyroidism. Both Td and GH treatments increased their growth rate, but neither of them was able to fully normalize body weights during the 1 -week replacement period (Fig. lb) .
Serum T4 and GH concentrations
Thyroid hormone serum levels of the hypothyroid untreated rats and the GH-treated animals were low, whereas those of the Td-replaced animals did not differ from the controls in either 18-day-old or adult rats (Table 1) . Random serum GH levels were also low in hypothyroid animals compared to control and hypothyroid-T4 replaced animals. As the anti-rat GH antibody used in the RIA does not crossreact with the human GH used in the study, the serum rat GH levels of the GH-treated hypothyroid pups were expectedly low (Table 1) .
Serum IGF levels
At the age of 18 days, serum IGF-I concentrations of the hypothyroid pups were approximately 50% of control levels (176 +Z 30.3 and 326 * 68.7 rig/ml, respectively). The difference was statistically significant (one-way ANOVA: F = 11.3, P = 0.002; P < 0.005 in Bonferroni f test). Thyroid hormone and GH replacement each corrected serum IGF-I values approximately to control level (372 & 30.0 and 299 & 35 .1 rig/ml, respectively). Serum IGF-II levels were similar in the hypothyroid and control groups (221 * 59.8 and 243 * 39.9 rig/ml, respectively), but they were significantly lower in the animals receiving either T* or GH replacement (87.3 & 13.3 and 124 Z!Z 6.2 rig/ml, respectively; one-way ANOVA: F = 14.7, P < 0.0001; P < 0.001 in Bonferroni f test). The paradoxical lowering of serum IGF-II in Th-replaced hypothyroid animals has been previously noted (19, 24) , although the reduction after GH replacement is a new observation (Table 1) .
Serum IGF-I levels of the adult hypothyroid rats (849 & 29 rig/ml) were approximately 50% of control levels (1650 & 97 rig/ml). The difference was statistically significant (oneway ANOVA: F = 25.2, P < 0.0001; P C 0.001 in Bonferroni f test). Serum IGF-I returned to control levels after 1 week of Ta replacement (1530 & 136 rig/ml). GH replacement, however, only partially corrected serum IGF-I levels (1310 * 161 rig/ml), which still differed significantly from control levels (P < 0.01). This value was, however, even more significantly different from the hypothyroid value (P < 0.001 in Bonferroni t test). Serum IGF-II concentrations were sim- FIG. 3. a, Western ligand blot of serum IGFBPs of the hypothyroid untreated (H), control (C), thyroid hormone replaced (+T), and GH replaced (+GH) adult animals. The two separate gels shown represent the same control and hypothyroid rat serum samples run with either sera from T4 or GH-replaced animals. Molecular weight markers are indicated. b, Respective densitometric data are shown. Mean and SD for each group are given, and statistical significance of the differences compared to control group is indicated (one-way ANOVA followed by Bonferroni t test ***, P < 0.001, **, P < 0.005). (Table 1) .
Serum IGFBPs
Western ligand blotting of the sera of the l&day-old animals showed a weak 38-44 kilodalton (kDa) band, representing the gradually emerging rat IGFBP-3 (rIGFBI'-3), a 28 kDa band, which we have earlier identified as rIGFBI'-2 by immunoprecipitation (19, 20) and a 22 kDa band, tentatively identified as rIGFBI'-4 (Fig. 2a.) . Hypothyroid pups showed significantly higher levels of IGFBP-2 than control animals (densitometric scanning readings for pooled samples in Fig. 2a: 1.59 and 0.64 AU X mm, respectively) demonstrating prolonged high expression of IGFBP-2 which we have described earlier (19). Thyroid hormone replacement completely normalized the elevated IGFBP-2 levels (0.47 AU X mm), whereas GH treatment had no effect (1.42 AU X mm; Fig. 2a ). This same IGFBP-2 expression pattern was mirrored by liver IGFBP-2 mRNA expression (Fig. 2b, again showing normalization with thyroid replacement, but not with GH. The just emerging IGFBP-3 band in the Western ligand blot was too weak to be quantitated reliably by densitometry, but it seemed to be increased in the Tb-replaced group. IGFBP-4 levels were remarkably similar between all the animals.
In the adult hypothyroid animals, there was a slight decrease in serum IGFBP-3 levels, and a 50% decrease in IGFBP-4 levels in comparison to control animals; both changes could be corrected by Td replacement. GH replacement, however, did not correct the decreased IGFBP-4 expression although it normalized the IGFBP-3 levels (Fig. 3,  a,b) . The levels of rIGFBl'-3 mRNA were decreased to 50% of control values in hypothyroid animals, and could be brought up to normal by either thyroid or GH replacement. IGFBP-4 mRNA levels were paradoxically higher in the hypothyroid animals. This change could be corrected by thyroid replacement, but not by GH treatment (Fig. 4, a,b) . No IGFBP-2 protein or mRNA (data not shown) could be detected in any of the adult animals.
Liver IGF receptors
Total specific IGF-I binding to crude liver membrane preparations from l&day-old pups did not differ between hypothyroid and control animals (4.0 & 0.7% and 4.4 k-1.7% specific binding per 50 mg membrane protein, respectively). The levels of type 1 and 2 IGF-receptor mRNA, measured by solution hybridization nuclease protection assay, were also similar between hypothyroid and control animals, in both age groups (Fig. 5, A,B) .
Discussion
Thyroid hormone is essential for normal mammalian growth, although its actions are not fully understood. There are several theories concerning the pathophysiology of growth failure associated with hypothyroidism. One explanation, supported by both in vivo and in vitro data on the regulation of GH production, is that the lack of thyroid hormone prevents normal GH secretion (7, 16, 17) or modulates GH receptor levels (11), leading to low serum IGF-I concentrations, and thus impaired somatic growth. King ef uZ. (12) relatively insensitive to thyroid hormone regulation, so that GH accumulation in rat pituitaries occurs independently of thyroid hormone until the sixth day of life (39). Poor weight gain in hypothyroid pups was evident from the first week of life, whereas Th replacement completely normalized the growth of the animals. GH substitution increased the growth rate of the hypothyroid animals, but could not correct it to control level, leading to body weights intermediate between hypothyroid and control groups. Glasstock et ~1. (40) have described a similar hormonal dependency of growth in neonatally hypophysectomized rats, with complete correction of growth requiring a combination of Th and GH replacement, and only partial correction with GH alone.
GH therapy, however, normalized the decreased serum IGF-I levels of the hypothyroid pups. Growth failure, despite normal serum IGF-I concentrations in GH-treated hypothyroid rats, has been described earlier (12), and provides indireceptors, and thus the IGF-I effects on target cells. This hypothesis is supported by the observation that thyroid hormone up-regulates IGF-I receptors and IGF-I binding in cultured pituitary cells (8, 37) . Increased serum thyroid hormone levels have also been shown to increase IGF-I binding to erythrocyte membranes (38). Third, other direct mechanisms, independent of the GH-IGF axis, have been suggested (13, 19) . Since regulation of IGFBP expression offers one possible level of regulation of the IGF system, we wanted to see if the IGFBP changes we have recently described in hypothyroid rats could be explained by any of the above mechanisms. The effects of hypothyroidism as well as those of Te or GH treatment of hypothyroid animals on their IGF system are summarized in Table 2 .
We began Th treatment for the thyroid hormone replacement group of the hypothyroid pups on the first postnatal day, since we have earlier demonstrated that the presence of thyroid hormone during the first week of life is critical for subsequent normal IGFBP ontogeny (21). Exogenous GH, on the other hand, was started on the fifth day of life, to avoid unphysiologically high serum GH levels during the first days of methimazole treatment, when the pups had not yet developed hypothyroidism and still had normally high postnatal GH secretion. The neonatal rat pituitary seems to be in support of the conclusion that thyroid hormone effects are not completely mediated via the GH-IGF-I pathway. The clinical experience that hypothyroidism blunts the growth response in GH treated GH-deficient children also supports this notion.
Both GH and T., treatment accelerated the ontogenic decline of serum IGF-II concentrations towards the normal adult levels, a still unexplained observation that we have made several times, with both neonatal hypothyroid and hypophysectomized rat models (19, 24) . This effect might be a sign of faster maturation of the IGF system in the presence of the exogenous hormones.
It might also be secondary to the simultaneous increase of serum IGF-I level, mediated by some regulatory interrelationship between the two growth factors.
We have previously described a change in IGFBP ontogeny in hypothyroid pups, with prolonged high expression of IGFBP-2, which is normalized by Td replacement (19). GH replacement, on the other hand, had no effect on the high IGFBP-2 serum protein or liver mRNA levels detected in hypothyroid animals at the age of 18 days. Thus, in the developing animal, thyroid regulation of serum IGF-I levels seems to be mediated by GH, but the effects on IGFBP-2 ontogeny, as well as part of the somatic growth response, involve some other mechanism.
The regulation of the ontogenie profile of IGFBP-2 seems thus to be a specific effect of thyroid hormone. Such changes in the IGF-IGFBP system may be mediating at the tissue level the maturation processes which thyroid hormone regulates during the perinatal period. 
